Technical analysis of Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Price Performance
| 1 month | +1.12% |
| 3 months | +1.98% |
| Year-to-date | +4.53% |
| 1 year | +5.55% |
52-Week Range
| 52-week High | $10.86 |
| 52-week Low | $10.26 |
| Avg Volume (90d) | 36K |
Technical Indicators
| SMA 50 | $10.73 |
| SMA 200 | $10.55 |
| Beta | -0.00 |
| 30-day Volatility (annualised) | 1.5% |
| Price vs SMA 50 | +1.1% |
| Price vs SMA 200 | +2.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $10.31 | |
| 2025-11 | $10.33 | +0.2% |
| 2025-12 | $10.37 | +0.4% |
| 2026-01 | $10.43 | +0.6% |
| 2026-02 | $10.46 | +0.3% |
| 2026-03 | $10.48 | +0.2% |
| 2026-04 | $10.53 | +0.5% |
| 2026-05 | $10.61 | +0.8% |
| 2026-06 | $10.65 | +0.4% |
| 2026-07 | $10.71 | +0.6% |
| 2026-08 | $10.75 | +0.4% |
| 2026-09 | $10.84 | +0.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $10.84 |
| Market Cap | $263M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 55.22 |
| Price / Book | 1.58 |
| EV / EBITDA | -99.55 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 0.02 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 17.88 |